- 1Laboratorio de Psicoinmunología, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Ciudad de México, Mexico
- 2Dirección General de Protección y Medicina Preventiva en el Transporte, Secretaría de Comunicaciones y Transportes, Ciudad de México, Mexico
- 3Centro de Investigaciones Científicas, Instituto de Química Aplicada, Universidad del Papaloapan, Oaxaca, Mexico
- 4Hospital Psiquiátrico Fray Bernardino Álvarez, Ciudad de México, Mexico
- 5Servicios Clínicos, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Ciudad de México, Mexico
Airline pilots are frequently exposed to numerous flights per week, changes in their circadian rhythms, and extended periods away from home. All these stressors make pilots susceptible to developing psychiatric disorders. Recently, emphasis has been placed on the need for molecular tests that help in the diagnosis of depression. The genes SLC6A4 and S100A10 encode serotonin transporter (SERT) and p11 protein, respectively. Their expression has been frequently associated with stress and depression. In this work, we quantified, by quantitative PCR, the expression of SERT and p11 in peripheral mononuclear cells of airline pilots compared to patients with depression and healthy volunteers. Moreover, by mass spectrometry, we quantified the serum serotonin levels in the same three groups. We found that SERT and p11 were overexpressed in the mononuclear cells of airline pilots and depressed patients compared to healthy volunteers. Although serum serotonin was not different between healthy volunteers and airline pilots, a decreasing trend was observed in the latter. As expected, serum serotonin in the patients was significantly lower. Alterations in SERT and p11 in airline pilots could be related to professional stress, a condition that could potentially affect their long-term mental health.
Introduction
Depression is a mood disorder characterized by the presence of symptoms such as deep sadness, loss of interest, difficulty experiencing pleasure, and feelings of guilt or low self-esteem. Other sleep and appetite disorders as well as feelings of fatigue and changes in body weight may also occur. Depression has a high prevalence, is the leading cause of disability, and contributes significantly to the global burden of disease. Additionally, it affects people of all ages (1–3) and the most serious cases can result in suicide. The etiology of depression is complex, involving several genetic, biological, and psychosocial factors. Among the biological factors are monoamine deficiency, neurotrophic disturbances, dysfunctional HPA activity, and inflammatory alterations. Since the etiology of depression is multifactorial, much remains to be studied about the molecular mechanisms underlying the pathophysiology of this disorder (4, 5).
In recent years, airplane accidents have raised concerns about aviation security and the mental health of airline pilots. In 2015, Flight 9,525 crashed in a mountainous region of France through a suicidal act of the pilot, who was suffering from depression (6). As a consequence, the European Aviation Safety Agency (EASA) recommended increasing aviation safety and improving the diagnostic methods for psychiatric disorders (7). Airline pilots live with high levels of stress due to their occupation (8); however, other factors, such as their social life and family problems, also contribute to their stressful life (9, 10). Several authors have stated that all of these factors make pilots susceptible to developing psychiatric disorders such as depression (10). The prevalence of depression in airline pilots is 1.9–12.6% (11) compared to 7.2–12.9% reported in the general population (12). The discrepancy in the prevalence of depression between airline pilots and the general population suggests that this disorder could be underdiagnosed in pilots. Currently, the diagnosis of depression is performed by a psychiatrist, according to the Diagnostic and Statistical Manual 5th edition (DSM-5), using structured interviews and rating scales, such as Mini-Mental State Examination (MMSE), Beck depression inventory (BDI), and Hamilton Depression Rating Scale (HDRS). In the past 50 years, several research projects have focused their efforts on searching for potential biomarkers of depression (13), such as serum biomarkers (14), catecholamine metabolites (15), among others (1, 2). From the development of the real-time quantitative PCR analysis (RT-qPCR), quantitative gene expression analysis has become an important tool in the search for biomarkers (14, 16–18). Both serotonin transporter (SERT) and p11 are proteins closely related to stress and depression (19–21). In lymphocytes of depressed patients, the increased gene expression of SERT (16, 18, 22) has been reported; meanwhile, p11 has been identified as a regulator of depressive-like behavior in animal models, showing a depressant (23) or anti-depressant (24) activity, depending on the brain region in which it is expressed. Moreover, the brain regions of subjects who have attempted suicide have shown reductions in p11 mRNA levels (24), and the protein has been proposed as a biomarker of post-traumatic stress disorder (PTSD) (20).
In this brief research report, we analyzed the gene expression of SERT and p11 in peripheral blood mononuclear cells (PBMCs) and measured the serum levels of serotonin in airline pilots compared to depressed patients and healthy volunteers. We found an increase in the gene expression of SERT and p11 in the PBMCs of airline pilots, as well as a decreasing trend in their serum serotonin levels.
Materials and Methods
Participant Recruitment
Airline pilots (AP), healthy volunteers (HV), and patients with depression (MDD) were recruited from 2015 to 2017 according to the protocol NC16044.0. All the participants agreed to participate in this study and signed the informed consent forms. They were evaluated by a certified psychiatrist applying the MMSE (Mini-Mental State Examination), BDI (Beck Depression Inventory), and HDRS (Hamilton Depression Rating Scale). The protocol NC16044.0 was approved by the corresponding research and ethics committees of the Instituto Nacional de Psiquiatría Ramón de la Fuente Muñíz (INPRFM), according to the international guidelines. The AP were recruited at the Secretaría de Comunicaciones y Transportes (SCT), Mexico, while HV and MDD were recruited at the INPRFM and Hospital Psiquiátrico Fray Bernardino Álvarez, Mexico. The inclusion and exclusion criteria are described in the flow diagram of Figure 1.
Figure 1. Flow diagram of participant recruitment. The figure describes the inclusion and exclusion criteria for healthy volunteers, airline pilots, and MDD patients.
PBMCs and RNA Isolation
We collected peripheral blood samples (10 mL) in tubes with sodium heparin (Becton Dickinson Vacutainer®, USA) by venepuncture. We isolated PBMCs using Ficoll-Histopaque (Histopaque-1077, Sigma-Aldrich) according to the manufacturer's instructions. PBMC isolation was performed within 2 h after blood sample collection. Immediately, the PBMC-containing pellet was homogenized in 1 mL TRIzol® and RNA isolation was performed according to the manufacturer's instructions. Samples were then stored at −80°C until cDNA synthesis.
Quantitative PCR of Serotonin Transporter and p11
The cDNA was synthesized from 1 μg total RNA pre-treated with 1 μL (1 U) DNase I (Invitrogen). Reverse transcription was performed using 1 μL (200 U) of MMLV reverse transcriptase (PROMEGA) according to the manufacturer's instructions. All qPCR reactions performed used 50 ng cDNA as template. The probes we used were Hs00169010_m1 (SLC6A4: gene name of serotonin transporter), Hs00751478_s1 (S100A10: gene name of p11), and Hs01060665_g1 (ACTB: gene name of β-actin), as well as TaqMan® Master Mix (ThermoFisher®). All assays were made in duplicate using CFX96TM REAL TIME SYSTEM® (BIORAD). We evaluated the system suitability for each qPCR assay by the R2 (≥0.99) and PCR efficiency (90–110%) parameters. The quantitative analysis was performed with the 2−ΔΔCt method (25), using the ΔCt mean of healthy volunteers as a calibrator to calculate the ΔΔCt.
Serum Serotonin Quantification by Liquid Chromatography Coupled to Mass Spectrometry
We measured serum levels of serotonin by reversed-phase Ultra High Performance Liquid Chromatography Electrospray-Ionization High Resolution Mass Spectrometry (UPLC-ESI-HRMS). Because not all serum samples were available, only 18 depressed patients, 14 airline pilots, and 7 healthy volunteers were included in this analysis. Firstly, we processed serum samples (1 mL) by adding 1 mL of a solution containing 5% citric acid, 2.5 mM L-lysine, and 2.5 mM EDTA. Then, proteins were precipitated with 200 μL 2.4 M perchloric acid at −20°C for 20 min. We obtained the supernatant containing serotonin by centrifugation at 14,000 × g at 4 °C for 15 min. After that, the serotonin was trapped and cleaned by solid phase extraction (SPE) using C18 cartridges (ThermoFisher®) and eluted with 250 μL acetonitrile. The serotonin extracts were vacuum dried and stored at −80°C until UPLC-ESI-HRMS analysis. Secondly, we resuspended serotonin extracts with 125 μL 0.1% (v/v) aqueous formic acid and filtered them through 0.22 μm PTFE membrane. We carried out the determination of serotonin (5-HT) by reversed-phase UPLC-ESI-HRMS according to the previous report (26) with modifications. In brief, we performed the analysis in an Acquity UPLC I-Class System (Waters) coupled to a Synapt G2-Si HDMS Q-TOF mass spectrometer (Waters) fitted with an ESI source. The LC-MS system and data were manipulated by MassLynx 4.1 software (Waters). The sample (5 μL) was injected onto a Luna Omega 1.6 μm C18 (2.1 × 150 mm, Phenomenex) using an isocratic separation with mobile phase composed of 4% (v/v) methanol in 0.1% aqueous formic acid delivered at a flow rate of 0.20 mL/min maintained at 40°C. The analysis time was 8 min and the column was cleaned between injections with 80% (v/v) methanol in 0.1% aqueous formic acid for 2 min. Ionization was performed in positive mode under the following conditions: capillary voltage, 3,000 V; capillary temperature, 120°C; sampling cone, 30 V; desolvation temperature, 300°C; and desolvation gas, 800 L/h. Full-scan mass spectra were acquired from 50 to 1,200 Da with acquisition data rate of 0.4 s and were corrected using leucine enkephalin as lock mass. For 5-HT quantification, the molecular ion [M+H-NH3]+ with exact mass 160.0762 was monitored.
Statistical Analysis
We performed a normality test using the Kolmogorov-Smirnov test for all data. The results of psychiatric tests, qPCR, HPLC-mass spectrometry, and demographic data were analyzed by the non-parametric Kruskal-Wallis and Dunn's multiple comparison tests. Correlation analysis were done following Spearman's correlation. All the statistical analyses were performed using GraphPad Prism version 8.0.0 for Windows (GraphPad Software, San Diego, California USA, www.graphpad.com). Significance was stablished when p < 0.05.
Results
Participants and Demographic Data
We recruited a total of 146 airplane pilots from 2015 to 2017; however, 67 were excluded since they did not meet the inclusion criteria, and the final number of airline pilots was 79. Moreover, we recruited 11 healthy volunteers and 39 patients with diagnosis of major depressive disorder (MDD) that met the inclusion criteria (Figure 1). Table 1 shows the demographic data from healthy volunteers, airline pilots, and MDD patients.
Table 1. Demographic data and psychiatric tests of healthy volunteers, Airline pilots, and MDD patients.
Psychiatric Tests
No airline pilot or healthy volunteer was diagnosed with depression, or any other psychiatric disorder, according to the results of MMSE, BDI, and HDRS tests. As expected, depressed patients had significantly higher scores in BDI (p < 0.001) and HDRS (p < 0.001) as compared to airline pilots and healthy volunteers (Table 1). We found no significant correlation (R ≥ 0.8) between psychiatric scores of HDRS and BDI and the 2−ΔΔCt values of p11 or SERT.
Elevated mRNA Levels of SERT and p11 in PBMCs of Airline Pilots and Depressed Patients
The RT-qPCR analysis showed that the expression of SERT was significantly higher in depressed patients (p < 0.001) and airline pilots (p < 0.001) as compared to healthy volunteers, with mean (standard error of mean) 2−ΔΔCt values of 101.3 (29.0), 13,986 (9,129), and 1.65(0.51), respectively (Figure 2A). The expression of p11 was also significantly higher in depressed patients (p < 0.01) and airline pilots (p < 0.001) compared to healthy volunteers, with mean 2−ΔΔCt values of 44.52 (18.29), 4,740 (2,785), and 1.34 (0.31), respectively (Figure 2B).
Figure 2. Gene expression of serotonin transporter and p11. Quantitative real time-PCR analysis of serotonin transporter (A) and p11 (B) in healthy volunteers (HV), airline pilots (AP), and depressed patients (MDD). Relative quantification performed by 2−ΔΔCt method. Statistical analysis was performed by Kruskal-Wallis with Dunn's multiple comparison test (**p < 0.01; ***p < 0.001). SEM, standard error of mean.
Serum Levels of Serotonin by UPLC-ESI-HRMS
We identified the full scan ESI-HRMS spectrum for serotonin, and it is shown in the Supplementary Figure 1. We found, as expected, that serum serotonin levels were significantly lower in depressed patients compared to airline pilots (p < 0.001) and healthy volunteers (p < 0.001), with mean values (standard error of mean) of 11.05 (2.54), 38.48 (6.27), and 58.42 ng/mL (17.75), respectively (Figure 3). Furthermore, we noted that the serum serotonin levels of airline pilots had a decreasing trend, although they were not statistically different or as low as those of depressed patients.
Figure 3. Serum serotonin levels. Serotonin quantification by UPLC-ESI-HRMS in healthy volunteers (HV), airline pilots (AP), and depressed patients (MDD). Statistical analysis was performed by Kruskal-Wallis with Dunn's multiple comparison test (***p < 0.001). SEM, standard error of mean.
Discussion
Since 1972, there have been 14 fatal events worldwide caused by the suicide of pilots while in flight, resulting in 562 deaths (27). Hence, airline pilots' mental health becomes particularly relevant in terms of aviation security. Factors such as the heavy workload and the frequent exposure to jet lag could contribute to a high level of stress and affect pilots' emotional stability. Stress and depression have such a close and strong relationship that the animal models used to study depressive disorders are based on stress models (28). Because of the stressful life of pilots (9), we decided to study their gene expression of SERT and p11 and their serum serotonin levels and compare them to those of depressed patients and healthy volunteers.
Our results showed that, as expected, HDRS and BDI scores were significantly higher in depressed patients than healthy volunteers and airline pilots. We must highlight that HDRS is a clinician-rated test, whereas BDI is a self-rated test. Thus, in HDRS, interpreting the psychiatrist is critical, while in BDI, the patient's perception of their symptoms is the most important. Moreover, many items of the HDRS scale focus on somatic symptoms of major depression, while BDI detects subjective/cognitive factors scarcely represented in HDRS (29, 30). The interpretive value required by clinical scales has motivated many authors to search for molecular parameters that may be useful in clinical diagnosis in conjunction with the psychiatric scales currently used.
In this sense, we found that airline pilots and depressed patients showed elevated mRNA levels of SERT and p11, compared to healthy volunteers. SERT and p11 have been strongly associated with stress and depression. Increased mRNA levels of SERT have been reported in lymphocytes of depressed patients (16, 18, 22); in contrast, other studies have reported reduced levels of the protein (21). Depressed patients have also been reported to show significantly reduced protein levels of SERT in brain regions such as the amygdala, striatum, and brainstem (31). Until now, the reason for the discrepancy between reduced protein levels and increased mRNA levels that have been reported in different works has not been fully clarified. For its part, p11 plays a role as a pharmacological mediator of antidepressants and regulator of serotonin receptor signaling and neurogenesis (19). Moreover, p11 has been proposed as a biomarker of post-traumatic stress (20). Recent studies using models of chronic unpredictable stress in mice have demonstrated the important role of p11 and epigenetic changes in its promoter in the development of depressive-like behavior (32). There is evidence that p11 interacts with 5-HT1B and 5-HT4 serotonin receptors and modulates their function (33–35) besides inducing the expression of 5-HT4, but there is no evidence of the direct interaction between p11 and SERT.
To our knowledge, this is the first work to report high mRNA levels of SERT and p11 in PBMC from airline pilots. Both genes are related to depression (16, 19) and play key roles in the functioning and regulation of the serotonergic system (35, 36). A dysfunctional serotonergic system leads to abnormal neurotransmission and the development of psychiatric disorders. Although our study was performed on peripheral blood cells, some authors have proposed that alterations in PBMC could be a reflection of alterations in the central nervous system (CNS) (37–39).
On the other hand, although the serotonin levels in airline pilots were not statistically different from those in healthy volunteers, we want to highlight that its decreasing trend is concerning. Serotonin is an important neurotransmitter with many physiological effects, and its proper functioning is necessary for mental health (40–42). Interestingly, depressive and suicide attempt patients have been reported to show low serum serotonin levels (43). Postmortem studies have revealed that 20% of pilots who died in fatal accidents had psychopathology or used selective serotonin reuptake inhibitors (SSRIs), but this was not reported in their latest medical examinations (44, 45). However, it has been shown that pilots who spend many hours flying per week and are frequently exposed to jet lag or alterations in their circadian rhythm are more likely to experience depressive or anxious symptoms (46, 47). In fact, pilots themselves have associated their fatigue with sleep deprivation and a heavy workload (48). Airline pilots are likely to deny their depressive symptoms or the use of antidepressants for fear of being suspended from work, posing a great risk to aviation. This triggers alarms in terms of aviation security and points out the importance of paying greater attention to the health of the aviation guild and the improvement of their working conditions. In addition, some reports have highlighted the lack of social support as a factor contributing to the deterioration of the pilots' mental health (9, 11).
Although our groups are unbalanced and heterogeneous, the sample size effect in our study is small when comparing MDD vs. AP. There are more women in the MDD group, but they are a minority in airline pilots and healthy volunteers. This is mainly due to the nature of the groups: Depression is higher in females than males, while most airline pilots are male. We are aware further studies are required in a larger and more diverse cohort; however, we cannot change the gender proportions of the groups, since this is a natural phenomenon. The issue of the differential sensitivity between men and women to develop mood disorders has been addressed by Kendler et al. (49). Kendler et al. reported that males are prone to suffer from introjective depression and females from anaclitic depression. Men are more likely to be emotionally invested in job and financial success; thus, the stress due to occupational activities (49), as in the case of airline pilots, could seriously affect their mental health.
In conclusion, in this brief research report, we show that airline pilots and depressed patients have similar alterations in their SERT and p11 profiles, distinguishing them from healthy volunteers. These alterations in airline pilots could be related to professional stress. Notably, this is the first SERT and p11 screening in this guild, and this work's prospects are to explore their potential as biomarkers in a larger and more diverse cohort.
Limitations of the Study
Future studies should consider the effect of sample size. Notably, there are more women in the group of patients with MDD while they are a minority in airline pilots and healthy volunteers. This is mainly due to the nature of the groups. We only use one housekeeping gene: β-actin. Due to their small size, platelets are a potential contaminant of PBMC. Still, the content of mRNA in platelets is considerably less than that of leukocytes; therefore, this greatly reduces contamination by genetic material.
Data Availability Statement
The original contributions presented in the study are included in the article/Supplementary Materials, further inquiries can be directed to the corresponding authors.
Ethics Statement
The studies involving human participants were reviewed and approved by Comité de Ética en Investigación del Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, México. Protocol: NC16044.0; Ref. CEI/C/081/2015. The patients/participants provided their written informed consent to participate in this study.
Author Contributions
LP, JJ-A, and GP-S: conceptualization. EB-V and MO-A: first draft of manuscript and experiments and data analysis. GP-S and EB-V: review and correction of manuscript. EB-V, MO-A, and SA-H: RT-qPCR experiments. SA-H and JLM: mononuclear cells and serum sample processing from patients and healthy volunteers. AL-T and OR-M: UHPLC-Mass spectrometry analysis. JJ-A: supervision and coordination of airline pilots' participation and depressed patients' participation. JM-C, OG-R, and JN-F: general administration and approval of the participation of airline pilots. MO-A and HS-G: mononuclear cells and serum sample processing of airline pilots. JJ-G, DM-C, AV-B, and AT-S: clinical evaluation of the participants. LP and GP-S: data curation and statistical analysis. LP: funding acquisition. All authors approved the final version of this manuscript.
Funding
This research was funded by the Ramón de la Fuente Muñíz National Institute of Psychiatry; SECITI: NC150048, SECITI (SECITI 0048/2014), CONACyT, FOSISS: SALUD-2017-1-289800 (NC16044.0), and CONACyT # INFRA-2015-01-252013.
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher's Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Acknowledgments
We thank José Valente Aguilar Zinser, Yessica Chaparro González, and Roberto Cepeda González for their support during their administration for the correct development of this work and Alberto Fernandez for his support in the transportation of samples from SCT to INPRFM. We appreciate the assistance of Erick Hernandez, Rosendo Del Angel, Ericka Flores Ortega, and Eliuth Juárez Cruz in the sample collection. We thank Dr. Francisco de la Peña for the careful and critical review of this work. We appreciate the assistance of Rosendo Del Angel in the literature collection.
Supplementary Material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpsyt.2022.859768/full#supplementary-material
Supplementary Figure 1. Full scan ESI-HRMS spectrum for serotonin. The most abundant peak (160.0762 m/z) corresponds to the fragmented ion of serotonin, whereas the least abundant (177.1025 m/z) corresponds to the precursor ion.
References
1. Pérez-Sánchez G, Becerril-Villanueva E, Arreola R, Martinez-Levi G, Hernández-Gutiérrez ME, Velasco-Velásquez MA, et al. Inflammatory profiles in depressed adolescents treated with fluoxetine: an 8-week follow-up, open study. Mediat Inflam. (2018) 2018:4074051. doi: 10.1155/2018/4074051
2. Becerril-Villanueva E, Pérez-Sánchez G, Alvarez-Herrera S, Girón-Pérez MI, Arreola R, Cruz-Fuentes C, et al. Alterations in the levels of growth factors in adolescents with major depressive disorder: a longitudinal study during the treatment with fluoxetine. Mediat Inflam. (2019) 2019:9130868. doi: 10.1155/2019/9130868
3. de la Peña FR, Cruz-Fuentes C, Palacios L, Girón-Pérez MI, Medina-Rivero E, Ponce-Regalado MD, et al. Serum levels of chemokines in adolescents with major depression treated with fluoxetine. World J Psychiatry. (2020) 10:175–86. doi: 10.5498/wjp.v10.i8.175
4. Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature. (2008) 455:894–902. doi: 10.1038/nature07455
5. Villas Boas GR, Boerngen de Lacerda R, Paes MM, Gubert P, Almeida WLDC, Rescia VC, et al. Molecular aspects of depression: a review from neurobiology to treatment. Eur J Pharmacol. (2019) 851:99–121. doi: 10.1016/j.ejphar.2019.02.024
6. Hussain SA, Malik MZ, Menezes RG. The airplane crash in the French Alps: a preventable tragedy. Asian J Psychiatr. (2015) 17:109–10. doi: 10.1016/j.ajp.2015.07.015
7. EASA. Task Force on Measures Following the Accident of Germanwings Flight 9525 Final Report. Cologne: EASA (2015). p. 1–19.
8. Indah Suci W. High level of work stressors increase the risk of mental-emotional disturbances among airline pilots. Med J Indonesia. (2007) 16:117–21. doi: 10.13181/mji.v16i2.267
9. Cooper CL, Sloan S. Occupational and psychosocial stress among commercial aviation pilots. J Occup Med. (1985) 27:570–6. doi: 10.1097/00043764-198508000-00014
10. Butcher JN. Assessing pilots with “the wrong stuff”: a call for research on emotional health factors in commercial aviators. Int J Select Assess. (2002) 10:168–84. doi: 10.1111/1468-2389.00204
11. Pasha T, Stokes PRA. Reflecting on the German wings disaster: a systematic review of depression and suicide in commercial airline pilots. Front Psychiatry. (2018) 9:86. doi: 10.1038/s41598-018-21243-x
12. Lim GY, Tam WW, Lu Y, Ho CS, Zhang MW, Ho RC. Prevalence of Depression in the Community from 30 Countries between 1994 and 2014 OPEN.
13. Papakostas GI, Shelton RC, Kinrys G, Henry ME, Bakow BR, Lipkin SH Pi B, et al. Assessment of a multi-assay, serum-based biological diagnostic test for major depressive disorder: a Pilot and Replication Study. Mol Psychiatry. (2013) 18:332–9. doi: 10.1038/mp.2011.166
14. Spijker S, Van Zanten JS, De Jong S, Penninx BWJH, Van Dyck R, Zitman FG, et al. Stimulated gene expression profiles as a blood marker of major depressive disorder. Biol Psychiatry. (2010) 68:179–86. doi: 10.1016/j.biopsych.2010.03.017
15. Quinones MP, Kaddurah-Daouk R. Metabolomics tools for identifying biomarkers for neuropsychiatric diseases. Neurobiol Dis. (2009) 35:165–76. doi: 10.1016/j.nbd.2009.02.019
16. Iga J, Ueno S, Yamauchi K, Motoki I, Tayoshi S, Ohta K, et al. Serotonin transporter mRNA expression in peripheral leukocytes of patients with major depression before and after treatment with paroxetine. Neurosci Lett. (2005) 389:12–6. doi: 10.1016/j.neulet.2005.06.048
17. Hepgul N, Cattaneo A, Zunszain PA, Pariante CM. Depression pathogenesis and treatment: what can we learn from blood mRNA expression? BMC Med. (2013) 11:28. doi: 10.1186/1741-7015-11-28
18. Watanabe SY, Iga JI, Ishii K, Numata S, Shimodera S, Fujita H, et al. Biological tests for major depressive disorder that involve leukocyte gene expression assays. J Psychiatr Res. (2015) 66–67:1–6. doi: 10.1016/j.jpsychires.2015.03.004
19. Svenningsson P, Kim Y, Warner-Schmidt J, Oh YS, Greengard P. P11 and its role in depression and therapeutic responses to antidepressants. Nat Rev Neurosci. (2013) 14:673–80. doi: 10.1038/nrn3564
20. Zhang L, Ursano RJ, Li H. P11: a potential biomarker for posttraumatic stress disorder. Methods Mol Biol. (2012) 829:453–68. doi: 10.1007/978-1-61779-458-2_29
21. Lima L, Urbina M. Serotonin transporter modulation in blood lymphocytes from patients with major depression. Cell Mol Neurobiol. (2002) 22:797–804. doi: 10.1023/A:1021869310702
22. Tsao CW, Lin YS, Chen CC, Bai CH, Wu SR. Cytokines and serotonin transporter in patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry. (2006) 30:899–905. doi: 10.1016/j.pnpbp.2006.01.029
23. Seo JS, Zhong P, Liu A, Yan Z, Greengard P. Elevation of p11 in lateral habenula mediates depression-like behavior. Mol Psychiatry. (2018) 23:1113–9. doi: 10.1038/mp.2017.96
24. Warner-Schmidt JL, Schmidt EF, Marshall JJ, Rubin AJ, Arango-Lievano M, Kaplitt MG, et al. Cholinergic interneurons in the nucleus accumbens regulate depression-like behavior. Proc Natl Acad Sci USA. (2012) 109:11360–5. doi: 10.1073/pnas.1209293109
25. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. (2008) 3:1101–8. doi: 10.1038/nprot.2008.73
26. Korse CM, Buning-Kager JCGM, Linders TC, Heijboer AC, van den Broek D, Tesselaar MET, et al. A serum and platelet-rich plasma serotonin assay using liquid chromatography tandem mass spectrometry for monitoring of neuroendocrine tumor patients. Clinica Chimica Acta. (2017) 469:130–5. doi: 10.1016/j.cca.2017.04.001
27. Aviation Safety Network. 1996-2017 Aviation Safety Database. Alexandria, VA: Aviation Safety Network (2016).
28. Willner P. The chronic mild stress (CMS) model of depression: history, evaluation and usage. Neurobiol Stress. (2016) 6:78–93. doi: 10.1016/j.ynstr.2016.08.002
29. Milak MS, Keilp J, Parsey RV, Oquendo MA, Malone KM, Mann JJ. Regional brain metabolic correlates of self-reported depression severity contrasted with clinician ratings. J Affect Disord. (2010) 126:113–24. doi: 10.1016/j.jad.2010.03.002
30. Linden M, Borchelt M, Barnow S, Geiselmann B. The impact of somatic morbidity on the Hamilton Depression Rating Scale in the very old. Acta Psychiatr Scand. (1995) 92:150–4. doi: 10.1111/j.1600-0447.1995.tb09559.x
31. Kambeitz JP, Howes OD. The serotonin transporter in depression: meta-analysis of in vivo and post mortem findings and implications for understanding and treating depression. J Affect Disord. (2015) 186:358–66. doi: 10.1016/j.jad.2015.07.034
32. Seo MK, Choi AJ, Seog D-H, Lee JG, Park SW. Early enriched environment prevents epigenetic p11 gene changes induced by adulthood stress in mice. Int J Mol Sci. (2021) 22:1928. doi: 10.3390/ijms22041928
33. Zhang X, Andren PE, Greengard P, Svenningsson P. Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in L-DOPA treatment of an animal model of Parkinsonism. Proc Natl Acad Sci USA. (2008) 105:2163–8. doi: 10.1073/pnas.0711839105
34. Svenningsson P, Chergui K, Rachleff I, Flajolet M, Zhang X, El Yacoubi M, et al. Alterations in 5-HT1B receptor function by p11 in depression-like states. Science. (2006) 311:77–80. doi: 10.1126/science.1117571
35. Warner-Schmidt JL, Flajolet M, Maller A, Chen EY, Qi H, Svenningsson P, et al. Role of p11 in cellular and behavioral effects of 5-HT4 receptor stimulation. J Neurosci. (2009) 29:1937–46. doi: 10.1523/JNEUROSCI.5343-08.2009
36. Szöllosi D, Stockner T. Investigating the mechanism of sodium binding to SERT using direct simulations. Front Cell Neurosci. (2021) 15:165. doi: 10.3389/fncel.2021.673782
37. Iga JI, Ueno SI, Ohmori T. Molecular Assessment of Depression from mRNAs in the Peripheral Leukocytes. doi: 10.1080/07853890802082088
38. van Heerden J, Conesa A, Stein D, Montaner D, Russell V, Illing N. Parallel changes in gene expression in peripheral blood mononuclear cells and the brain after maternal separation in the mouse. BMC Res Notes. (2009) 2:1–10. doi: 10.1186/1756-0500-2-195
39. Arosio B, D'Addario C, Gussago C, Casati M, Tedone E, Ferri E, et al. Peripheral blood mononuclear cells as a laboratory to study dementia in the elderly. BioMed Res Int. (2014) 2014:169203. doi: 10.1155/2014/169203
40. Manchia M, Carpiniello B, Valtorta F, Comai S. Serotonin dysfunction, aggressive behavior, and mental illness: exploring the link using a dimensional approach. ACS Chem Neurosci. (2017) 8:961–72. doi: 10.1021/acschemneuro.6b00427
41. Mohammad-Zadeh LF, Moses L, Gwaltney-Brant SM. Serotonin: a review. J Vet Pharmacol Ther. (2008) 31:187–99. doi: 10.1111/j.1365-2885.2008.00944.x
42. Arreola R, Becerril-Villanueva E, Cruz-Fuentes C, Velasco-Velázquez MA, Garcés-Alvarez ME, Hurtado-Alvarado G, et al. Immunomodulatory effects mediated by serotonin. J Immunol Res. (2015) 2015:354957. doi: 10.1155/2015/354957
43. Saldanha D, Kumar N, Ryali VSSR, Srivastava K, Pawar AA. Serum serotonin abnormality in depression. Med J Armed Forces India. (2009) 65:108–12. doi: 10.1016/S0377-1237(09)80120-2
44. Akin A, Chaturvedi AK. Selective serotonin reuptake inhibitors in pilot fatalities of civil aviation accidents, 1990-2001. Aviat Space Environ Med. (2003) 74:1169–76. doi: 10.1037/e734372011-001
45. Sen A, Akin A, Canfield DV, Chaturvedi AK. Medical histories of 61 aviation accident pilots with postmortem SSRI antidepressant residues. Aviation Space Environ Med. (2007) 78:1055–9. doi: 10.3357/ASEM.2030.2007
46. O'Hagan AD, Issartel J, Nevill A, Warrington G. Flying into depression. Workplace Health Safety. (2017) 65:109–17. doi: 10.1177/2165079916659506
47. Walker WH, Walton JC, DeVries AC, Nelson RJ. Circadian rhythm disruption and mental health. Transl Psychiatry. (2020) 10:1–13. doi: 10.1038/s41398-020-0694-0
48. Reis C, Mestre C, Canhão H, Gradwell D, Paiva T. Sleep complaints and fatigue of airline pilots. Sleep Sci. (2016) 9:73–7. doi: 10.1016/j.slsci.2016.05.003
Keywords: stress, depression, airline pilots, serotonin transporter, p11
Citation: Becerril-Villanueva E, Olvera-Alvarez MI, Alvarez-Herrera S, Maldonado-García JL, López-Torres A, Ramírez-Marroquín OA, González-Ruiz O, Nogueira-Fernández JM, Mendoza-Contreras JM, Sánchez-García HO, José-Alfallo JA, Valencia Baños A, Torres-Serrano AB, Jiménez-Genchi J, Mendieta-Cabrera D, Pérez-Sánchez G and Pavón L (2022) Screening of SERT and p11 mRNA Levels in Airline Pilots: A Translational Approach. Front. Psychiatry 13:859768. doi: 10.3389/fpsyt.2022.859768
Received: 21 January 2022; Accepted: 23 February 2022;
Published: 23 March 2022.
Edited by:
Michael Kluge, University Hospital Leipzig, GermanyReviewed by:
Anoop Kumar, Delhi Pharmaceutical Sciences and Research University, IndiaThomas Steinkellner, Medical University of Vienna, Austria
Copyright © 2022 Becerril-Villanueva, Olvera-Alvarez, Alvarez-Herrera, Maldonado-García, López-Torres, Ramírez-Marroquín, González-Ruiz, Nogueira-Fernández, Mendoza-Contreras, Sánchez-García, José-Alfallo, Valencia Baños, Torres-Serrano, Jiménez-Genchi, Mendieta-Cabrera, Pérez-Sánchez and Pavón. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Gilberto Pérez-Sánchez, Z2lsYmVydG8ucGVyZXouc2FuY2hleiYjeDAwMDQwO2ltcC5lZHUubXg=; Lenin Pavón, bGt1cmlha2kmI3gwMDA0MDtpbXAuZWR1Lm14
†These authors have contributed equally to this work and share first authorship